Avapritinib, a targeted therapy for patients with GIST harboring the PDGFRα D842V mutation, has shown significant efficacy with an overall response rate of 86% in the NAVIGATOR study. The French Long Term Registry aims to collect real-world data on the long-term effectiveness and safety of avapritinib, which is crucial for market positioning and reimbursement strategies. The temporary authorization for use (ATUc) in France reflects a favorable regulatory environment, but the need for comprehensive patient data may influence future market access and pricing strategies. The competitive landscape includes imatinib, sunitinib, and regorafenib, but avapritinib's specific efficacy in D842V mutation patients positions it uniquely in the market.